Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: A longitudinal study
Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: A longitudinal study
复制标题
DOI：
10.1016/j.lfs.2010.10.006
复制
发表时间：
2010-12-18
期刊：
影响因子：
6.1
通讯作者：
Nishizawa, Yoshiki
中科院分区：
文献类型：
--
作者：
Okamoto, Keiji;Inaba, Masaaki;Nishizawa, Yoshiki
目的：研究利塞膦酸对绝经后女性骨质疏松症患者动脉增厚和硬化的影响。主要方法：对33例服用利塞膦酸酯(2.5 mg/d)的患者和30例未服用利塞膦酸酯的患者(对照组)进行为期1年的监测。检测两组患者的骨代谢指标、股骨颈骨密度(BMD)、臂踝脉搏波速度(BaPWV)和颈动脉内膜厚度(CA-IMT)。FN骨密度与CA-IMT、baPWV呈显著负相关。在研究期间，利塞膦酸钠组的FN骨密度显著增加(p=0.0097)，而对照组的FN骨密度显著降低(p=0.0013)。利塞膦酸组BaPWV和CA-IMT无明显变化，而对照组BaPWV和CA-IMT显著升高。在研究期间，在所有受试者(服用利塞膦酸盐的患者和对照组)中，FN骨密度的百分比变化与baPWV(r=-0.294，p=0.0262)和CA-IMT(r=-0.305，p=0.0234)呈显著负相关。意义：除了增加骨密度外，利塞膦酸盐显著抑制绝经后骨质疏松症患者一年内动脉增厚和硬化的进展。这些变化可能间接归因于利塞膦酸盐对骨骼的影响。(C)2010 Elsevier Inc.保留所有权利。
Aims: A longitudinal study was performed to examine the effect of risedronate on arterial thickening and stiffening in postmenopausal female osteoporosis patients.Main methods: Patients treated with risedronate (2.5 mg/day) (n=33) and those that did not receive risedronate (n=30, control group) were monitored over a 1-year period. Bone metabolic markers, bone mineral density (BMD) of the femur neck (FN), brachial-ankle pulse wave velocity (baPWV), and intimamedia thickness at the carotid artery (CA-IMT) were measured.Key findings: At baseline, there was no significant difference in blood pressure, serum lipid profiles, FN BMD, baPWV and CA-IMT between the risedronate-treated patients and the controls. Baseline levels of FN BMD were significantly negatively correlated with those of CA-IMT and baPWV. During the study, FN BMD increased significantly in the risedronate group (p=0.0097), but decreased significantly in the control group (p=0.0013). BaPWV and CA-IMT did not change significantly in the risedronate group, but both increased significantly in the control group. The percentage change in FN BMD over the study period showed a significant negative correlation with those for baPWV (r=-0.294, p=0.0262) and CA-IMT (r=-0.305, p=0.0234) in all subjects (risedronate-treated patients and controls).Significance: In addition to increasing BMD, risedronate significantly suppressed the progression of arterial thickening and stiffening in postmenopausal osteoporotic patients over one year. These changes may indirectly be due to the effect of risedronate on bone. (C) 2010 Elsevier Inc. All rights reserved.